Publications by authors named "David D Bowtell"

100Publications

Noncanonical IL6 Signaling-Mediated Activation of YAP Regulates Cell Migration and Invasion in Ovarian Clear Cell Cancer.

Cancer Res 2020 Nov 11;80(22):4960-4971. Epub 2020 Sep 11.

Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-19-3044DOI Listing
November 2020

Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.

Authors:
Filipe Correia Martins Dominique-Laurent Couturier Anna Paterson Anthony N Karnezis Christine Chow Tayyebeh M Nazeran Adekunle Odunsi Aleksandra Gentry-Maharaj Aleksandra Vrvilo Alexander Hein Aline Talhouk Ana Osorio Andreas D Hartkopf Angela Brooks-Wilson Anna DeFazio Anna Fischer Arndt Hartmann Brenda Y Hernandez Bryan M McCauley Chloe Karpinskyj Christiani B de Sousa Claus Høgdall Daniel G Tiezzi Esther Herpel Florin Andrei Taran Francesmary Modugno Gary Keeney Gregg Nelson Helen Steed Honglin Song Hugh Luk Javier Benitez Jennifer Alsop Jennifer M Koziak Jenny Lester Joseph H Rothstein Jurandyr M de Andrade Lene Lundvall Luis Paz-Ares Luis Robles-Díaz Lynne R Wilkens Maria J Garcia Maria P Intermaggio Marie-Lyne Alcaraz Mary A Brett Matthias W Beckmann Mercedes Jimenez-Linan Michael Anglesio Michael E Carney Michael Schneider Nadia Traficante Nadja Pejovic Naveena Singh Nhu Le Peter Sinn Prafull Ghatage Ramona Erber Robert Edwards Robert Vierkant Roberta B Ness Samuel Leung Sandra Orsulic Sara Y Brucker Scott H Kaufmann Sian Fereday Simon Gayther Stacey J Winham Stefan Kommoss Tanja Pejovic Teri A Longacre Valerie McGuire Valerie Rhenius Weiva Sieh Yurii B Shvetsov Alice S Whittemore Annette Staebler Beth Y Karlan Cristina Rodriguez-Antona David D Bowtell Ellen L Goode Estrid Høgdall Francisco J Candido Dos Reis Jacek Gronwald Jenny Chang-Claude Kirsten B Moysich Linda E Kelemen Linda S Cook Marc T Goodman Peter A Fasching Robin Crawford Suha Deen Usha Menon David G Huntsman Martin Köbel Susan J Ramus Paul D P Pharoah James D Brenton

Br J Cancer 2020 Sep 18;123(5):793-802. Epub 2020 Jun 18.

Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, England.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-0900-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463007PMC
September 2020

Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).

Authors:
Aline Talhouk Joshy George Chen Wang Timothy Budden Tuan Zea Tan Derek S Chiu Stefan Kommoss Huei San Leong Stephanie Chen Maria P Intermaggio Blake Gilks Tayyebeh M Nazeran Mila Volchek Wafaa Elatre Rex C Bentley Janine Senz Amy Lum Veronica Chow Hanwei Sudderuddin Robertson Mackenzie Samuel C Y Leong Geyi Liu Dustin Johnson Billy Chen Aocs Group Jennifer Alsop Susana N Banerjee Sabine Behrens Clara Bodelon Alison H Brand Louise Brinton Michael E Carney Yoke-Eng Chiew Kara L Cushing-Haugen Cezary Cybulski Darren Ennis Sian Fereday Renée T Fortner Jesús García-Donas Aleksandra Gentry-Maharaj Rosalind Glasspool Teodora Goranova Casey S Greene Paul Haluska Holly R Harris Joy Hendley Brenda Y Hernandez Esther Herpel Mercedes Jimenez-Linan Chloe Karpinskyj Scott H Kaufmann Gary L Keeney Catherine J Kennedy Martin Köbel Jennifer M Koziak Melissa C Larson Jenny Lester Liz-Anne Lewsley Jolanta Lissowska Jan Lubiński Hugh Luk Geoff Macintyre Sven Mahner Iain A McNeish Janusz Menkiszak Nikilyn Nevins Ana Osorio Oleg Oszurek José Palacios Samantha Hinsley Celeste L Pearce Malcolm C Pike Anna M Piskorz Isabelle Ray-Coquard Valerie Rhenius Cristina Rodriguez-Antona Raghwa Sharma Mark E Sherman Dilrini De Silva Naveena Singh Peter Sinn Dennis Slamon Honglin Song Helen Steed Euan A Stronach Pamela J Thompson Aleksandra Tołoczko Britton Trabert Nadia Traficante Chiu-Chen Tseng Martin Widschwendter Lynne R Wilkens Stacey J Winham Boris Winterhoff Alicia Beeghly-Fadiel Javier Benitez Andrew Berchuck James D Brenton Robert Brown Jenny Chang-Claude Georgia Chenevix-Trench Anna deFazio Peter A Fasching María J García Simon A Gayther Marc T Goodman Jacek Gronwald Michelle J Henderson Beth Y Karlan Linda E Kelemen Usha Menon Sandra Orsulic Paul D P Pharoah Nicolas Wentzensen Anna H Wu Joellen M Schildkraut Mary Anne Rossing Gottfried E Konecny David G Huntsman Ruby Yun-Ju Huang Ellen L Goode Susan J Ramus Jennifer A Doherty David D Bowtell Michael S Anglesio

Clin Cancer Res 2020 Oct 17;26(20):5411-5423. Epub 2020 Jun 17.

British Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-20-0103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572656PMC
October 2020

Germline whole exome sequencing of a family with appendiceal mucinous tumours presenting with pseudomyxoma peritonei.

BMC Cancer 2020 May 1;20(1):369. Epub 2020 May 1.

Research Division, Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Victorian Comprehensive Cancer Centre Building, 305 Grattan St., Melbourne, Victoria, VIC 3000, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-020-6705-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195761PMC
May 2020

Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer.

Hematol Oncol Clin North Am 2018 12;32(6):983-996

Cancer Research Division, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, Victoria 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria 3010, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2018.07.007DOI Listing
December 2018

Ovarian Carcinoma-Associated Mesenchymal Stem Cells Arise from Tissue-Specific Normal Stroma.

Stem Cells 2019 02 2;37(2):257-269. Epub 2018 Nov 2.

Division of Hematology Oncology, Department of Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/stem.2932DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392140PMC
February 2019

Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.

Authors:
Peter F Rambau Robert A Vierkant Maria P Intermaggio Linda E Kelemen Marc T Goodman Esther Herpel Paul D Pharoah Stefan Kommoss Mercedes Jimenez-Linan Beth Y Karlan Aleksandra Gentry-Maharaj Usha Menon Susanna Hernando Polo Francisco J Candido Dos Reis Jennifer Anne Doherty Simon A Gayther Raghwa Sharma Melissa C Larson Paul R Harnett Emma Hatfield Jurandyr M de Andrade Gregg S Nelson Helen Steed Joellen M Schildkraut Micheal E Carney Estrid Høgdall Alice S Whittemore Martin Widschwendter Catherine J Kennedy Frances Wang Qin Wang Chen Wang Sebastian M Armasu Frances Daley Penny Coulson Micheal E Jones Micheal S Anglesio Christine Chow Anna de Fazio Montserrat García-Closas Sara Y Brucker Cezary Cybulski Holly R Harris Andreas D Hartkopf Tomasz Huzarski Allan Jensen Jan Lubiński Oleg Oszurek Javier Benitez Fady Mina Annette Staebler Florin Andrei Taran Jana Pasternak Aline Talhouk Mary Anne Rossing Joy Hendley Robert P Edwards Sian Fereday Francesmary Modugno Roberta B Ness Weiva Sieh Mona A El-Bahrawy Stacey J Winham Jenny Lester Susanne K Kjaer Jacek Gronwald Peter Sinn Peter A Fasching Jenny Chang-Claude Kirsten B Moysich David D Bowtell Brenda Y Hernandez Hugh Luk Sabine Behrens Mitul Shah Audrey Jung Prafull Ghatage Jennifer Alsop Kathryn Alsop Jesús García-Donas Pamela J Thompson Anthony J Swerdlow Chloe Karpinskyj Alicia Cazorla-Jiménez María J García Susha Deen Lynne R Wilkens José Palacios Andrew Berchuck Jennifer M Koziak James D Brenton Linda S Cook Ellen L Goode David G Huntsman Susan J Ramus Martin Köbel

J Pathol Clin Res 2018 10 21;4(4):250-261. Epub 2018 Sep 21.

Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, AB, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cjp2.109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174617PMC
October 2018

Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.

Gynecol Oncol 2018 08 26;150(2):239-246. Epub 2018 May 26.

Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia; The University of Sydney, Sydney, New South Wales, Australia; Department of Gynaecological Oncology, Westmead Hospital, Westmead, New South Wales, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.05.020DOI Listing
August 2018

MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.

Mayo Clin Proc 2018 03;93(3):307-320

Department of Health Sciences Research, Mayo Clinic, Rochester, MN. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2017.10.023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870793PMC
March 2018

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.

Authors:
Ellen L Goode Matthew S Block Kimberly R Kalli Robert A Vierkant Wenqian Chen Zachary C Fogarty Aleksandra Gentry-Maharaj Aleksandra Tołoczko Alexander Hein Aliecia L Bouligny Allan Jensen Ana Osorio Andreas Hartkopf Andy Ryan Anita Chudecka-Głaz Anthony M Magliocco Arndt Hartmann Audrey Y Jung Bo Gao Brenda Y Hernandez Brooke L Fridley Bryan M McCauley Catherine J Kennedy Chen Wang Chloe Karpinskyj Christiani B de Sousa Daniel G Tiezzi David L Wachter Esther Herpel Florin Andrei Taran Francesmary Modugno Gregg Nelson Jan Lubiński Janusz Menkiszak Jennifer Alsop Jenny Lester Jesús García-Donas Jill Nation Jillian Hung José Palacios Joseph H Rothstein Joseph L Kelley Jurandyr M de Andrade Luis Robles-Díaz Maria P Intermaggio Martin Widschwendter Matthias W Beckmann Matthias Ruebner Mercedes Jimenez-Linan Naveena Singh Oleg Oszurek Paul R Harnett Peter F Rambau Peter Sinn Philipp Wagner Prafull Ghatage Raghwa Sharma Robert P Edwards Roberta B Ness Sandra Orsulic Sara Y Brucker Sharon E Johnatty Teri A Longacre Eilber Ursula Valerie McGuire Weiva Sieh Yanina Natanzon Zheng Li Alice S Whittemore deFazio Anna Annette Staebler Beth Y Karlan Blake Gilks David D Bowtell Estrid Høgdall Francisco J Candido dos Reis Helen Steed Ian G Campbell Jacek Gronwald Javier Benítez Jennifer M Koziak Jenny Chang-Claude Kirsten B Moysich Linda E Kelemen Linda S Cook Marc T Goodman María José García Peter A Fasching Stefan Kommoss Suha Deen Susanne K Kjaer Usha Menon James D Brenton Paul DP Pharoah Georgia Chenevix-Trench David G Huntsman Stacey J Winham Martin Köbel Susan J Ramus

JAMA Oncol 2017 12;3(12):e173290

School of Women’s and Children’s Health, University of New South Wales, Sydney, Australia

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2017.3290DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5744673PMC
December 2017

Mechanisms and clinical implications of tumor heterogeneity and convergence on recurrent phenotypes.

J Mol Med (Berl) 2017 11 4;95(11):1167-1178. Epub 2017 Sep 4.

Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00109-017-1587-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296823PMC
November 2017

Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer.

J Clin Oncol 2017 Apr 13;35(12):1274-1280. Epub 2017 Feb 13.

Elizabeth L. Christie, Sian Fereday, Ken Doig, Sarah-Jane Dawson, and David D.L. Bowtell, Peter MacCallum Cancer Centre, Melbourne; Elizabeth L. Christe, Ken Doig, Sarah-Jane Dawson, David D.L. Bowtell, University of Melbourne, Melbourne, Victoria; and Swetansu Pattnaik and David D.L. Bowtell, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.4627DOI Listing
April 2017

Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.

J Clin Oncol 2017 Jul 11;35(20):2329-2337. Epub 2017 Apr 11.

Goli Samimi, Charlisse F. Caga-anan, Michael Dean, Leah E. Mechanic, Lori M. Minasian, and Mark E. Sherman, National Cancer Institute; Lawrence C. Brody, National Human Genome Research Institute, Bethesda, MD; Marcus Q. Bernardini, Stephanie Lheureux, Patricia A. Shaw, Princess Margaret Cancer Centre, Toronto, Ontario; Janice S. Kwon, University of British Columbia; British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Ian G. Campbell, Paul A. James, Masataka Takenaka, and David D. Bowtell, Peter MacCallum Cancer Centre; David D. Bowtell, University of Melbourne, Melbourne, Victoria; Georgia Chenevix-Trench, QIMR Berghofer Medical Research Institute, Brisbane, Queensland; Michael Friedlander, The Prince of Wales Hospital; Susan J. Ramus, University of New South Wales; Susan J. Ramus and David D. Bowtell, Garvan Institute of Medical Research, Sydney, New South Wales, Australia; Fergus J. Couch, Mayo Clinic, Rochester, MN; Joanne A. de Hullu and Marline G. Harmsen, Radboud University Medical Center, Nijmegen, the Netherlands; Susan M. Domchek and Ronny Drapkin, University of Pennsylvania, Philadelphia; Phuong L. Mai, Magee-Women's Hospital of the University of Pittsburgh Medical Center, Pittsburgh, PA; Heather Spencer Feigelson, Kaiser Permanente Institute for Health Research, Denver, CO; Mia M. Gaudet, American Cancer Society, Atlanta, GA; Karen Hurley and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mark E. Robson, Weill Cornell Medical College, New York, NY; Felicitas Lacbawan, Quest Diagnostics Nichols Institute, San Juan Capistrano; Thomas P. Slavin, City of Hope, Duarte, CA; Evan R. Myers, Duke University Medical Center, Durham, NC; Lisa F. Rezende, FORCE: Facing Our Risk of Cancer Empowered, Tampa; Mark E. Sherman, Mayo Clinic, Jacksonville, FL; and Elizabeth M. Swisher, University of Washington Medical Center, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.3439DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501360PMC
July 2017

Commentary on "Epithelial-to-Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer".

Cancer Res 2016 12;76(24):7075-7077

Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-16-3022DOI Listing
December 2016

A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers.

Cancer Res 2017 02 6;77(4):971-981. Epub 2016 Dec 6.

Children's Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales Australia, Kensington, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-15-2906DOI Listing
February 2017

Blood Worth Bottling: Circulating Tumor DNA as a Cancer Biomarker.

Cancer Res 2016 10;76(19):5590-5591

Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia. The Kinghorn Cancer Centre, Garvan Institute for Medical Research, Darlinghurst, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-16-2281DOI Listing
October 2016

Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.

Gynecol Oncol 2016 Sep 18;142(3):458-64. Epub 2016 Jul 18.

The Westmead Institute for Medical Research, The University of Sydney, Sydney, NSW, Australia; Department of Gynecological Oncology, Westmead Hospital, Sydney, NSW, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2016.06.023DOI Listing
September 2016

Long-term survival of patients with mismatch repair protein-deficient, high-stage ovarian clear cell carcinoma.

Histopathology 2017 Jan 21;70(2):309-313. Epub 2016 Sep 21.

School for Women's and Infants' Health, University of Western Australia, Perth, Western Australia, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.13040DOI Listing
January 2017

PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations.

J Natl Cancer Inst 2016 Mar 27;108(3). Epub 2016 Jan 27.

Affiliations of authors:CR-UK Department of Oncology, University of Cambridge, Strangeways Research Laboratory , Cambridge, UK (PDPP, HS, ED, PH, CB); Department of Preventive Medicine, Keck School of Medicine , USC/NorrisComprehensive Cancer Center, University of Southern California , CA (MPI, SAG, SJR); Peter MacCallum Cancer Centre, East Melbourne , Victoria , Australia (KA, AOCSG, DDB); Westmead Millennium Institute, Westmead Hospital , Sydney , Australia (AOCSG); The QIMR Berghofer Medical Research Institute , Brisbane , Australia (AOCSG); Gynaecology Research Unit, Hannover Medical School , Hannover , Germany (NB, TD); Radiation Oncology Research Unit, Hannover Medical School , Hannover , Germany (NB); Mother and Child Hospital , Minsk , Belarus (NB); Department of Health Science Research, Division of Epidemiology, Mayo Clinic , Rochester, MN (MSC, JMC, ELG); Department of Biostatistics, University of Kansas Medical Center , KS (BLF); Gynaecological Cancer Research Centre, Women's Cancer, Institute for Women's Health, University College London , London, UK (AGM, MW, UM); Clinics of Obstetrics and Gynaecology, Hannover Medical School , Hannover , Germany (PH); Department of Gynecological Oncology, Roswell Park Cancer Institute , Buffalo, NY (SL, SP, KO); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center , Los Angeles, CA (JL, BYK); Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine , Stanford, CA (VM, WS, ASW); Department of Cancer Prevention and Control, Roswell Park Cancer Institute , Buffalo, NY (KBM, LSC); Department of Obstetrics and Gynecology, Duke University Medical Center , Durham, NC (OCAC); Department of Biochemistry and Molecular Biology, University of Melbourne , Melbourne, Victoria , Australia (DDB); Sir Peter MacCallum Department of Oncology, University of Melbourne , Melbourne, Victoria , Australia (DDB); Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London , London, UK (DDB).

View Article

Download full-text PDF

Source
https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnc
Publisher Site
http://dx.doi.org/10.1093/jnci/djv347DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072371PMC
March 2016

The ubiquitin ligase Siah2 regulates obesity-induced adipose tissue inflammation.

Obesity (Silver Spring) 2015 Nov 18;23(11):2223-32. Epub 2015 Sep 18.

Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/oby.21220DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633373PMC
November 2015

Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.

J Natl Cancer Inst 2015 Nov 27;107(11). Epub 2015 Aug 27.

Department of Preventive Medicine, Keck School of Medicine, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA (SJR, MPI, CKE, DC, SAG); CR-UK Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK (HS, ED, JPT, PH, JA, PDPP); Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK (ANR, LF, AGM, JH, SP, CA, UM, IJJ); Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK (DB, ACA); Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia (DDB, KA, GM, AOCSSG); Department of Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Victoria, Australia (DDB); Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia (DDB, GM); Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK (DDB); Westmead Millennium Institute, Westmead Hospital, Sydney, Australia (AOCSSG); The QIMR Berghofer Medical Research Institute, Brisbane, Australia (AOCSSG); Department of Health Sciences Research, Mayo Clinic, Rochester, MN (MSC, JMC, ELG); Department of Biostatistics, University of Kansas Medical Center, Andover, KS (BLF); Department of Histopathology, Addenbrooke's Hospital, Cambridge, UK (MJL); Department of Gynecological Oncology, Roswell Park Cancer Institute, Buffalo, NY (SP, SL, KO); Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY (LSC, KBM); Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, CA (WS, VM, ASW); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center (JL, BYK); Gynaecology Research Unit, Hannover Medical School, Hannover, Germany (NB, TD); Radiation Oncology Research Unit, Hannover Medical School, Hannover,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djv214DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643629PMC
November 2015

Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.

J Clin Oncol 2015 Sep 10;33(26):2901-7. Epub 2015 Aug 10.

Honglin Song, Ed Dicks, Jonathan P. Tyrer, Patricia Harrington, Jennifer Alsop, and Paul D.P. Pharoah, University of Cambridge; Mercedes Jimenez-Linan, Addenbrooke's Hospital, Cambridge; Jane Hayward, Lindsay Fraser, Susan Philpott, Christopher Anderson, Adam Rosenthal, Aleksandra Gentry-Maharaj, Usha Menon, and Ian J. Jacobs, University College London; David D. Bowtell, Imperial College London, London; Ian J. Jacobs, University of Manchester and Manchester Academic Health Science Centre, Manchester, United Kingdom; Susan J. Ramus, Maria P. Intermaggio, Christopher K. Edlund, David Conti, and Simon A. Gayther, University of Southern California, Los Angeles, CA; David D. Bowtell and Kathryn Alsop, Peter MacCallum Cancer Centre, East Melbourne; David D. Bowtell, University of Melbourne, Melbourne, Victoria, Australia; Mine S. Cicek, Julie M. Cunningham, and Ellen L. Goode, Mayo Clinic, Rochester, MN; Brooke L. Fridley, University of Kansas Medical Center, Kansas City, KS; Estrid Høgdall, Allan Jensen, and Susanne Krüger, Danish Cancer Society Research Center; Estrid Høgdall, Herlev Hospital, University of Copenhagen; Claus K. Høgdall and Susanne Krüger, Rigshospitalet, Copenhagen, Denmark; Jan Lubiński, Tomasz Huzarski, Anna Jakubowska, and Jacek Gronwald, Pomeranian Medical University, Szczecin, Poland; and Samantha Poblete, Shashi Lele, Lara Sucheston-Campbell, Kirsten B. Moysich, and Kunle Odunsi, Roswell Park Cancer Institute, Buffalo, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.2408DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4554751PMC
September 2015

Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors.

Genome Med 2015 7;7(1):87. Epub 2015 Aug 7.

Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria Australia ; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria Australia ; Department of Pathology, University of Melbourne, Parkville, Victoria Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13073-015-0210-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4528310PMC
August 2015

Loss of heterozygosity: what is it good for?

BMC Med Genomics 2015 Aug 1;8:45. Epub 2015 Aug 1.

Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12920-015-0123-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522148PMC
August 2015

Whole-genome characterization of chemoresistant ovarian cancer.

Nature 2015 May;521(7553):489-94

1] Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia [2] Department of Pathology, University of Melbourne, Parkville, Victoria 3052, Australia [3] Sir Peter MacCallum Cancer Centre Department of Oncology, University of Melbourne, Parkville, Victoria 3052, Australia [4] Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London W12 0HS, UK [5] Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, Victoria 3052, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature14410DOI Listing
May 2015

Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.

Mol Cancer Ther 2015 Jun 7;14(6):1495-503. Epub 2015 Apr 7.

Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. Department of Pathology, The University of Melbourne, Parkville, Victoria, Australia. Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-15-0039DOI Listing
June 2015

The ubiquitin ligase Siah is a novel regulator of Zeb1 in breast cancer.

Oncotarget 2015 Jan;6(2):862-73

Tumour Microenvironment Laboratory, QIMR Berghofer Medical Research Institute, Herston 4006, Australia.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359261PMC
http://dx.doi.org/10.18632/oncotarget.2696DOI Listing
January 2015

Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.

Clin Cancer Res 2014 Dec 14;20(24):6618-30. Epub 2014 Oct 14.

Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia. Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia. University of Sydney, Westmead Hospital, Sydney, New South Wales, Australia. Westmead Institute for Cancer Research, Westmead Millennium Institute, Westmead Hospital, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1292DOI Listing
December 2014

ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.

J Natl Cancer Inst 2014 Jul 23;106(7). Epub 2014 Jun 23.

Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju149DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110473PMC
July 2014

Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts.

Mol Oncol 2014 May 24;8(3):656-68. Epub 2014 Jan 24.

The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia; Royal Women's Hospital, Parkville, Victoria 3052, Australia; Department of Medical Biology, University of Melbourne, Parkville, Victoria 3052, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2014.01.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4400120PMC
May 2014

Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.

Cancer Res 2014 Feb 23;74(4):1141-52. Epub 2013 Dec 23.

Authors' Affiliations: Department of Medical Oncology; Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; Harvard Medical School; Department of Pathology, Division of Cytogenetics; Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Boston, Massachusetts; Peter MacCallum Cancer Centre, East Melbourne; Department of Oncology, Peter MacCallum Cancer Centre; Departments of Pathology and Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-2247DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517944PMC
February 2014

Synthetic lethality between CCNE1 amplification and loss of BRCA1.

Proc Natl Acad Sci U S A 2013 Nov 11;110(48):19489-94. Epub 2013 Nov 11.

Department of Research, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1314302110DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845173PMC
November 2013

Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.

J Pathol 2013 Dec;231(4):413-23

The Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; The Department of Pathology, University of Melbourne, Parkville, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.4251DOI Listing
December 2013

Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.

Eur J Cancer 2013 Dec 3;49(18):3936-44. Epub 2013 Sep 3.

Oncogenic Signalling and Growth Control Program, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett St, Melbourne, Victoria 8006, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria 3010, Australia; Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, Victoria 3010, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2013.08.007DOI Listing
December 2013

Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.

Clin Cancer Res 2013 Nov 4;19(21):5960-71. Epub 2013 Sep 4.

Authors' Affiliations: Peter MacCallum Cancer Centre, East Melbourne; Victorian Cancer Cytogenetics Service, St Vincent's Hospital, Melbourne; Sir Peter MacCallum Department of Oncology; Departments of Pathology, Biochemistry and Molecular Biology, and Medicine; Centre for Translational Pathology, University of Melbourne, Parkville, Victoria, Australia; Dana-Farber Cancer Institute, Boston; and The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/early/2013/08/
Web Search
http://clincancerres.aacrjournals.org/content/19/21/5960.ful
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-1337DOI Listing
November 2013

Identifying associations between genomic alterations in tumors.

Methods Mol Biol 2013 ;1049:9-19

Cancer Genetics and Genomics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-62703-547-7_2DOI Listing
March 2014

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.

Lancet Oncol 2013 Aug 9;14(9):853-62. Epub 2013 Jul 9.

Division of Epidemiology, Department of Health Research and Policy, Stanford University, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(13)70253-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006367PMC
August 2013

Siah2-deficient mice show impaired skin wound repair.

Wound Repair Regen 2013 May-Jun;21(3):437-47. Epub 2013 Apr 29.

Health Innovations Research Institute, School of Medical Sciences, RMIT University, Bundoora.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/wrr.12045DOI Listing
December 2013

RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary.

J Pathol 2013 Feb;229(3):469-76

Victorian Breast Cancer Research Consortium (VBCRC), Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.4134DOI Listing
February 2013

Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations.

Clin Cancer Res 2012 Oct 13;18(19):5267-77. Epub 2012 Aug 13.

Centre for Cancer Genomics and Predictive Medicine, Peter MacCallum Cancer Centre, East Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-1103DOI Listing
October 2012

Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche.

Cancer Res 2012 Aug 2;72(16):3906-11. Epub 2012 Jul 2.

Cancer Genomics and Genetics Laboratory, Cancer Immunology Program, and Metastasis Research Group, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-11-3873DOI Listing
August 2012

The changing view of high-grade serous ovarian cancer.

Cancer Res 2012 Jun 16;72(11):2701-4. Epub 2012 May 16.

Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-11-3911DOI Listing
June 2012

Vascular normalization by loss of Siah2 results in increased chemotherapeutic efficacy.

Cancer Res 2012 Apr 21;72(7):1694-704. Epub 2012 Feb 21.

Cancer Genomics and Genetics, Peter MacCallum Cancer Centre, St Andrew's Place, East Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-11-3310DOI Listing
April 2012

A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment.

Cancer Res 2012 Jan 7;72(1):66-75. Epub 2011 Nov 7.

Centre for Cancer and Inflammation, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, Cancer Research UK, Bioinformatics and Biostatistics Service, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-11-2178DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3252703PMC
January 2012